twittertopbarlinks_eventstopbarlinks_requesttopbarlinks_archives
NCMA Algae Tips
Click here for more information about Liqofluxphenometrics515R1
Visit cricatalyst.com!Commercial Algae Professionals spacer

Money

Euglena soaring on Japanese stock exchange

May 20, 2013
AlgaeIndustryMagazine.com

Kengo Suzuki, head of Research and Development at Euglena Co., works in the company's laboratory in Tokyo. Euglena, a venture formed by the University of Tokyo, has soared 10-fold this year for the second-best performance on the Tokyo Stock Exchange Mothers Index.

Kengo Suzuki, head of Research and Development at Euglena Co., works in the company’s laboratory in Tokyo. Euglena, a venture formed by the University of Tokyo, has soared 10-fold this year for the second-best performance on the Tokyo Stock Exchange Mothers Index. Photographer: Tomohiro Ohsumi/Bloomberg

Satoshi Kawano & Kanoko Matsuyama report for Bloomberg.com that a Japanese biotech venture focused on making jet fuel from algae is soaring in Tokyo trading as cash being pumped into the economy by the central bank cascades into speculative investments.

“The market expects quantitative and qualitative easing to continue long term, boosting liquidity and drawing investors to speculative shares like biotech,” said Kazuyuki Terao, chief investment officer at Allianz Global Investors Japan.

Euglena, a venture formed by the University of Tokyo, has soared 10-fold this year for the second-best performance on the Tokyo Stock Exchange Mothers Index. The company is developing single-cell algae based products including jet fuel, which it expects to supply steadily by 2018, its President, Mitsuru Izumo, said in an interview.

The venture is currently valued at about 157 billion yen (15.35 million USD) and trades at about 335 times forecast earnings. Still, Japan’s fastest-rising biotech companies have yet to produce steady profit, so the investors’ bets are speculative, said Terao of Allianz Global.

The JASDAQ index had an average price earnings ratio of about 22, based on analyst estimates for the year, while the Tokyo Stock Exchange Mother’s Index, which includes Euglena, averaged about 74 times earnings estimated by analysts, according to data compiled by Bloomberg.

The multiples for many of the companies aren’t prohibitively high, said Tomohiko Ikeno, an analyst at Ace Research Institute. “It is still a good time to invest in some Japanese biotech ventures to hold long term,” Ikeno said. “The stocks will be volatile in the short term, but still have great potential for gains.”

More Like This…

HOME A.I.M. Archives

Copyright ©2010-2016 AlgaeIndustryMagazine.com. All rights reserved. Permission required to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

From The A.I.M. Archives

— Refresh Page for More Choices
Nevele, Belgium-based TomAlgae is developing freeze-dried microalgae for feed in shrimp hatcheries. The company has created its own microalgal “cultivar” and manufactures...
Northwestern University researchers have developed a quantitative tool that might help bring back coral from the brink of extinction. The novel algorithm could help asses...
Tom Lindfors writes in the New Richmond News about how the Roberts, Wisconsin, wastewater treatment plant – considered a minor utility designed to treat an average flow o...
Global Algae Innovations, with headquarters in San Diego, California, and cultivation/production facilities in Lihue, Hawaii, have introduced a new algae harvesting syste...
Cellana, Inc., a leading developer of algae-based products for sustainable nutrition and energy applications, and PIVEG, Inc., a leader in high-specification ingredients ...
In one of the most comprehensive studies to date, University of North Carolina at Chapel Hill researchers have sequenced the genes of a harmful algal bloom, unveiling nev...